How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,818 results for

Severe Persistent Asthma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. An evaluation of the effects of saffron supplementation on the asthma clinical symptoms and asthma severity in patients with mild and moderate persistent allergic asthma: a double-blind, randomized placebo-controlled trial. (Full text)

An evaluation of the effects of saffron supplementation on the asthma clinical symptoms and asthma severity in patients with mild and moderate persistent allergic asthma: a double-blind, randomized placebo-controlled trial. Asthma is a heterogeneous disease which is usually associated with chronic airway inflammation. Saffron has anti-inflammatory effects and may has beneficial effects on asthma.The present study was intended to survey the effects of saffron supplementation on blood pressure (...) of clinical symptoms of the patients (i.e., frequency of the shortness of breath during the day and night time, use of salbutamol spray, waking up due to asthma symptoms and activity limitation) in comparison to the placebo (p < 0.001). Besides, asthma severity decreased almost significantly in the saffron group (p = 0.07). It was also found that saffron, in comparison with the placebo, significantly reduced the systolic and diastolic blood pressure, triglycerides and low density lipoprotein cholesterol

2019 Respiratory research PubMed

2. Bronchial thermoplasty for moderate or severe persistent asthma in adults. (Full text)

Bronchial thermoplasty for moderate or severe persistent asthma in adults. Bronchial thermoplasty is a procedure that consists of the delivery of controlled radiofrequency-generated heat via a catheter inserted into the bronchial tree of the lungs through a flexible bronchoscope. It has been suggested that bronchial thermoplasty works by reducing airway smooth muscle, thereby reducing the ability of the smooth muscle to bronchoconstrict. This treatment could then reduce asthma symptoms (...) and exacerbations, resulting in improved asthma control and quality of life.To determine the efficacy and safety of bronchial thermoplasty in adults with bronchial asthma.We searched the Cochrane Airways Group Specialised Register of Trials (CAGR) up to January 2014.We included randomised controlled clinical trials that compared bronchial thermoplasty versus any active control in adults with moderate or severe persistent asthma. Our primary outcomes were quality of life, asthma exacerbations and adverse

2014 Cochrane PubMed

3. Bronchial thermoplasty for the treatment of severe persistent asthma

Bronchial thermoplasty for the treatment of severe persistent asthma Appl Applic Date o Context at www 1. An Ass thermop Departm 2. After co and cos for BT populat effectiv 3. MSAC severe a is defin combin procedu airways broncho compris The pat severe a that con lication N cant: of MSAC c t for decisio w.msac.gov. Purpose o essment Re plasty (BT) ment of Hea MSAC’s a onsidering t st-effectiven for the treat tion, its plac veness and r Summary noted that t asthma desp ned as the m ned with a lo (...) ure involvin s through a oscope unde ses three pro tient popula asthma who nfirmation r Pub No. 1384 s onsiderat on: MSAC m au of applica eport reques for severe p alth in Octo advice to t the availabl ness of bron tment of sev ce in the clin resulting un y of consid this applicat pite treatme maximal inha ong-acting b ng the delive single use c er moderate ocedures w ation for the ose asthma s required tha lic Sum – Bronc severe p Bos ion: MS makes its ad tion and l sting Medic persistent a ber

2015 Medical Services Advisory Committee

4. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation

Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation

2013 NIHR HTA programme

5. Confounders of severe asthma: diagnoses to consider when asthma symptoms persist despite optimal therapy (Full text)

Confounders of severe asthma: diagnoses to consider when asthma symptoms persist despite optimal therapy Asthma can often be challenging to diagnose especially when patients present with atypical symptoms. Therefore, it is important to have a broad differential diagnosis for asthma to ensure that other conditions are not missed. Clinicians must maintain a high index of suspicion for asthma mimickers, especially when patients fail to respond to conventional therapy. The purpose of this review (...) is to briefly review some of the more common causes of asthma mimickers that clinicians should consider when the diagnosis of asthma is unclear.

2018 The World Allergy Organization journal PubMed

6. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. (Full text)

taking tapering doses of ICS alone (RR 2.44, 95% CI 1.52 to 3.92; 621 participants; two studies; moderate quality), but deaths were too infrequent for researchers to draw any conclusions about mortality. Data showed no improvement in lung function nor in asthma control measures.For adolescents and adults with persistent asthma, with suboptimal asthma control with daily use of ICS, the addition of anti-leukotrienes is beneficial for reducing moderate and severe asthma exacerbations and for improving (...) Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Asthma management guidelines recommend low-dose inhaled corticosteroids (ICS) as first-line therapy for adults and adolescents with persistent asthma. The addition of anti-leukotriene agents to ICS offers a therapeutic option in cases of suboptimal control with daily ICS.To assess the efficacy and safety of anti-leukotriene agents added to ICS compared with the same dose

2017 Cochrane PubMed

7. Bronchial thermoplasty for the treatment of severe persistent asthma

Bronchial thermoplasty for the treatment of severe persistent asthma Bronchial thermoplasty for the treatment of severe persistent asthma Bronchial thermoplasty for the treatment of severe persistent asthma Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Bronchial thermoplasty (...) for the treatment of severe persistent asthma. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1384. 2015 Authors' objectives Bronchial thermoplasty (BT) is performed in a bronchoscopy/endoscopy suite and takes about an hour to complete each of the three required treatments. BT is usually conducted under moderate sedation. Post-procedure, patients are observed and monitored for approximately 2-4 hours. Authors' conclusions After considering the available evidence presented in relation

2015 Health Technology Assessment (HTA) Database.

8. Omalizumab Treatment for Atopic Severe Persistant Asthma: A Single-Center, Long-Term, Real-Life Experience with 38 Patients (Full text)

Omalizumab Treatment for Atopic Severe Persistant Asthma: A Single-Center, Long-Term, Real-Life Experience with 38 Patients Omalizumab is a monoclonal antibody that is used as add-on therapy for treating moderate-to-severe persistant atopic asthma in patients with persistant symptoms and frequent exacerbations, despite step 4 treatment according to GINA guidelines. Real-life studies on omalizumab treatment are limited in Turkey. Thus, the present study aims to assess the clinical efficacy (...) and treatment outcomes of omalizumab in patients with atopic severe persistant asthma.Patients with atopic severe persistant asthma who were treated with omalizumab between 2009 and 2017 were retrospectively evaluated. Baseline and last results of the following variables were compared: symptom scores (GINA categorical), controller medications, blood eosinophil counts, forced expiratory volume in 1 second (FEV1) values, and the number of exacerbations that were treated with systemic corticosteroids

2018 Turkish Thoracic Journal PubMed

9. Serum vitamin A, zinc and visual function in children with moderate to severe persistent asthma. (PubMed)

Serum vitamin A, zinc and visual function in children with moderate to severe persistent asthma. Asthma is a common childhood disorder with complex pathobiologic components that may include aspects of nutritional deficit. The contribution of vitamin deficiency, specifically vitamin A, as part of the disease complex has not been well studied, particularly among at risk children. In this study, we examined the prevalence of vitamin A as well as zinc deficiency in conjunction with visual function (...) among an urban pediatric population sample with moderate-severe persistent asthma.A cross-sectional case-control assessment of serum vitamin A, zinc and visual function among urban children with and without asthma was undertaken. Inclusion criteria involved (1) well-controlled pediatric asthmatic patients between the ages of 8-18 with corrected vision of at least 20/25 in each eye and (2) chronic use of a combination beta agonist-steroid inhaler. Visual function was assessed by Snellen visual acuity

2018 Journal of Asthma

10. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population. (PubMed)

Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population. Real-world studies on the effectiveness of omalizumab in Egyptian population with asthma are limited. This study aimed to evaluate the real-world effectiveness and safety of omalizumab as an add-on treatment in pediatric and adult patients with severe, persistent allergic asthma in Egypt.The primary endpoint of this 16-week (...) observed in the safety analysis of omalizumab as add-on treatment.Outcomes of this real-world study were consistent with previous effectiveness and safety studies of omalizumab. Omalizumab was effective and well tolerated for the management of severe, persistent IgE-mediated asthma in pediatric and adult patients in Egypt.

2018 Journal of Asthma

11. Benralizumab (Fasenra) - treatment in adult patients with severe eosinophilic asthma

the submitting company. ? Symptoms of severe asthma include difficulty breathing and limited mobility, leaving many people housebound. Persistent symptoms may also lead to sleep deprivation, feelings of despair and depression, low activity levels, weight gain and increased dependence on family and carers. Additionally, repeated hospital admissions may lead to further social isolation and economic disadvantage. ? People with severe asthma require intensive therapies to control symptoms and prevent attacks (...) Benralizumab (Fasenra) - treatment in adult patients with severe eosinophilic asthma 1 Published 10 June 2019 1 SMC2155 benralizumab 30mg solution for injection in pre filled syringe (Fasenra®) AstraZeneca UK Limited 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission

2019 Scottish Medicines Consortium

12. Different evolution in the treatment of a severe persistent asthma in 2 twins: Case report and review of the literature. (Full text)

Different evolution in the treatment of a severe persistent asthma in 2 twins: Case report and review of the literature. Asthma is a multifactorial disease with complex genetic inheritance. In children under the age of 5 years, the diagnosis of asthma is a challenge.We present the case of twin sisters under the same treatment for persistent asthma, but with different evolution over the time.One of the sister is diagnosed with severe persistent bronchial asthma associated with bronchiectasis (...) pulmonary function tests. The other one had a more complicated evolution which led to a severe crisis by the age of 10 years old.Although asthma is a multifactorial disease with complex genetic inheritance, the genetics has its limits. Our twins had a similar onset with the same genetic inheritance, with the same risk factors, with the same comorbidities and with the same treatment. In this context, different evolutions of severe persistent asthma require more extensive genetic investigations.We present

2017 Medicine PubMed

13. Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. (PubMed)

Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. A proportion of severe asthma patients suffers from persistent airflow limitation (PAL), often associated with more symptoms and exacerbations. Little is known about the underlying mechanisms. Here, our aim was to discover unexplored potential mechanisms using Gene Set Variation Analysis (GSVA), a sensitive technique that can detect underlying pathways in heterogeneous samples.Severe (...) enriched gene signatures were identified in nasal brushings (n=1), sputum (n=9), bronchial brushings (n=1) and bronchial biopsies (n=4) that were associated with response to inhaled steroids, eosinophils, interleukin-13, interferon-α, specific CD4+ T-cells and airway remodelling.PAL in severe asthma has distinguishable underlying gene networks that are associated with treatment, inflammatory pathways and airway remodelling. These findings point towards targets for the therapy of PAL in severe

2017 European Respiratory Journal

14. Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial. (PubMed)

Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial. Combination therapy of inhaled corticosteroid/long acting β2-agonist (ICS/LABA) is the cornerstone of managing asthmatics who are uncontrolled with low-medium dose of ICS. The novel ICS/LABA combination of fluticasone propionate and formoterol (flu/form) provides potent anti-inflammatory and rapid bronchodilatory effect (...) . This randomized, multi-centre, double-blind study compared the efficacy and safety of flu/form (125/6 mcg BD; Maxiflo®) with the well-established budesonide/formoterol combination (bud/form 200/6 mcg BD), both delivered through a pressurized metered dose inhaler (pMDI) in patients with moderate to severe persistent asthma over 12 weeks.This study enrolled patients between 18 and 65 years. The primary end-point was to demonstrate non-inferiority for the mean change in the pre-dose morning peak expiratory flow

2017 Pulmonary Pharmacology & Therapeutics

15. Comparison of fluticasone propionate with budesonide administered via nebulizer: a randomized controlled trial in patients with severe persistent asthma. (Full text)

Comparison of fluticasone propionate with budesonide administered via nebulizer: a randomized controlled trial in patients with severe persistent asthma. This study compared the efficacy and safety of fluticasone propionate (FP) inhalation n solution with budesonide (BUD) suspension for inhalation administered via nebulizer, in Chinese adult patients with severe, persistent asthma.This was a multicenter, randomized, active-controlled, single-blind, parallel-group study, conducted at 26 clinical (...) of the 95% CIs for LS mean treatment difference in morning PEF change from baseline over weeks 1-4 in a post hoc analysis were -10.41 and -11.96 L/min in the ITT and PP populations respectively; both above -12.00 L/min. A review of safety data indicated that rates of AEs, SAEs, and drug-related AEs were similar between two groups.The 12-week treatment of FP inhalation solution administered via nebulizer is safe and effectively for treating severe, persistent asthma in Chinese patients over 12 week.

2017 Journal of thoracic disease PubMed

16. Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years

Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03387241

2017 Clinical Trials

17. A trial of oral corticosteroids for persistent systemic and airway inflammation in severe asthma (Full text)

A trial of oral corticosteroids for persistent systemic and airway inflammation in severe asthma The fraction of exhaled nitric oxide (FeNO) and blood eosinophils, markers of local and systemic eosinophilic inflammation, respectively, are increased in asthmatic patients. Little is known concerning the relationship between the FeNO levels and blood eosinophils in asthmatics.Twenty severe asthmatics with persistent FeNO elevation (≥40 ppb) and blood eosinophilia (≥3%) despite maintenance therapy (...) eosinophils. There were significant differences in the ACQ score between the steroid response group and poor response group (P < 0.005). The group in which both FeNO and blood eosinophils were suppressed fulfilled the change in score of ≥0.5 on the ACQ.In the patients with severe asthma, responses to systemic corticosteroids were variable in terms of FeNO and blood eosinophils. It was necessary to suppress both persistent eosinophilia and high FeNO for the improvement of asthma control.© 2017 The Authors

2017 Immunity, Inflammation and Disease PubMed

18. Meta-analysis of the efficacy and safety of bronchial thermoplasty in patients with moderate-to-severe persistent asthma. (Full text)

Meta-analysis of the efficacy and safety of bronchial thermoplasty in patients with moderate-to-severe persistent asthma. This meta-analysis assessed the efficacy and safety of a novel intervention for asthma, bronchial thermoplasty (BT), in patients with moderate-to-severe persistent asthma. An electronic literature search identified three randomized controlled trials (RCT) of BT that recruited 421 patients in total. Outcomes of interest were the Asthma Quality of Life Questionnaire (AQLQ (...) period. Additional long-term RCT are required to confirm whether BT provides benefit to patients with moderate-to-severe persistent asthma.

2017 The Journal of international medical research PubMed

19. Atopy, but Not Obesity is Associated with Asthma Severity Among Children with Persistent Asthma. (Full text)

Atopy, but Not Obesity is Associated with Asthma Severity Among Children with Persistent Asthma. Obesity is associated with an increased risk of asthma in children. Atopic sensitization is a major risk factor for asthma including severe asthma in children. It is unclear if obesity is associated with worse asthma control or severity in children and how its effects compare to atopy. We sought to examine relationships of weight status and atopy to asthma control and severity among a population (...) of predominantly low income, minority children and adolescents with persistent asthma.A cross-sectional analysis of 832 children and adolescents, age range 5-17 years, with persistent asthma was performed. Clinical assessments included asthma questionnaires of symptoms, asthma severity score, health care utilization and medication treatment step, lung function testing, and skin prick testing as well as measures of adiposity. Data were collected between December 2010 and August 2014 from Johns Hopkins Hospital

2016 Journal of Asthma PubMed

20. FACTORS AFFECTING ABILITY TO ACHIEVE ASTHMA CONTROL IN ADULT PATIENTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA. (PubMed)

FACTORS AFFECTING ABILITY TO ACHIEVE ASTHMA CONTROL IN ADULT PATIENTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA. Despite the use of optimal therapy and guidelines, the rate of asthma control is suboptimal in adult populations. Purpose of this study is to describe factors associated with ability to achieve well-controlled asthma over time for adult patients treated in a tertiary medical center-based asthma outpatient specialty clinic.Existing clinical data collected for 320 adult patients (...) rhinitis (p = 0.769) were not independently significant. Body-mass-index (BMI) in combination with adherence did influence ability to achieve well-controlled asthma (p < 0.05). Adherence (p = 0.615), allergic rhinitis (p = 0.172), BMI continuous scale (p = 0.074) and visit interval <90 days (p = 0.653) were not independently associated with likelihood of achieving well-controlled asthma in severe persistent asthmatics. Significance of particular factors in combination (adherence, allergic rhinitis, sex

2016 Journal of Asthma

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>